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Stroke: Vascular and Interventional Neurology
ORIGINAL RESEARCH

Thrombectomy for Large-Vessel Occlusion
With Pretreatment Intracranial Hemorrhage
Daniel A. Tonetti, MD; Shashvat M. Desai, MD; Stephanie Casillo, BS; Sohum Desai, MD; Ameer E. Hassan, DO;
Gabriel Flores-Milan, MD; Maxim Mokin, MD; Mudassir Farooqui, MD; Santiago Ortega-Gutierrez, MD;
Ashutosh P. Jadhav, MD
BACKGROUND: Many patients treated with endovascular thrombectomy (EVT) in clinical practice would not have qualified for
inclusion in the initial clinical trials demonstrating benefit for EVT, yet likely will benefit from reperfusion. One such subset for
which data are sparse is patients with emergent large-vessel occlusion and concomitant intracranial hemorrhage (ICH). The
objective of this report is to document patients who underwent thrombectomy for large-vessel occlusion in the presence of
concomitant ICH and evaluate their clinical characteristics and outcomes.
METHODS: We retrospectively reviewed prospectively collected patient records at 4 comprehensive stroke centers
from 2012 to 2019. Patients were identified who had pre-EVT ICH. Data collected included baseline patient
demographics and laboratory values, stroke characteristics, ICH radiographic variables, antiplatelet/anticoagulant/
thrombolytic medication use, and procedural factors. The primary safety outcome was any worsening of ICH on neuroimaging
obtained 24 hours after EVT.
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RESULTS: Eight patients were identified who underwent thrombectomy with concomitant ICH. The mean age was 71.9 years
(range, 37–90). Median National Institutes of Health Stroke Scale score was 25 (interquartile range, 16.5–28.8), and 5 (63%)
received tissue plasminogen activator. All patients underwent EVT and had mTICI2B or greater reperfusion. In 7 patients (88%),
the initial ICH remained stable on postprocedure imaging. In 1 patient who received intravenous antiplatelet agents during
thrombectomy, the hemorrhagic transformation was radiographically increased but without clinical correlate or mass effect.
CONCLUSIONS: In a multi-institution evaluation of 8 patients with ICH at the time of thrombectomy, 1 patient had radiographic
worsening of hemorrhage, and no patient experienced clinical worsening related to hemorrhage progression. These findings
suggest that thrombectomy may be safe in this population.

Key Words: acute ischemic stroke  intracranial hemorrhage  thrombectomy

s a result of robust large randomized controlled clinical trials, current guidelines recommend endovascular thrombectomy (EVT) for a
subset of patients with emergent large-vessel occlusion (LVO) with salvageable penumbra.1 Many patients
treated with EVT in clinical practice would not have
qualified for inclusion in the initial clinical trials demonstrating benefit for EVT, yet likely will benefit from

A

thrombectomy.2,3 Consensus guidelines on the role of
EVT in unique populations who fall outside of traditional clinical trial populations have been published.4
However, data regarding the role of EVT inpatients
with emergent LVO and concomitant intracranial hemorrhage (ICH) are lacking.
Patients with emergent LVO and concurrent ICH
represent a unique population in whom the utility of EVT
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Nonstandard Abbreviations and Acronyms

Clinical Perspective

ECASS European-Australasian Acute Stroke
Study
EVT
endovascular thrombectomy
ICH
intracranial hemorrhage
LVO
large-vessel occlusion
NIHSS National Institutes of Health Stroke
Scale

• In this multi-institutional retrospective analysis
of patients with prethrombectomy intracranial
hemorrhage, no patient had clinical worsening related to hemorrhage progression after
mechanical thrombectomy.

have not been studied but who may benefit from EVT.
We hypothesized that these patients were unlikely to
have worsening of their ICH after thrombectomy. The
objective of this report is to document patients who
underwent thrombectomy for LVO in the presence of
concomitant ICH and evaluate their clinical characteristics and outcomes.

• Mechanical thrombectomy for large-vessel
occlusion may be safe in patients with
prethrombectomy intracranial hemorrhage.

TABLE 1.

Baseline Characteristics
All patients

N

8

Age, y, mean (range)
Female, n (%)
NIHSS score, median (IQR)
Antiplatelet use, n (%)

METHODS
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We retrospectively reviewed prospectively collected
patient records at 4 academic American comprehensive stroke centers from 2012 to 2019. Patients were
identified who had pre-EVT ICH. Each center had
institutional review board approval to collect and review
data.
Data collected included baseline patient demographics and laboratory values, stroke characteristics,
ICH radiographic variables, antiplatelet/anticoagulant/
thrombolytic medication use, and procedural factors.
Outcomes were evaluated including follow-up cranial imaging, hematoma stability, reperfusion grading,
necessity for clot evacuation or decompressive craniectomy, National Institutes of Health Stroke Scale (NIHSS)
score at discharge, and 90-day modified Rankin scale
scores.

71.9 (37–90)
5 (63)
25 (16.5–28.8)
2 (25)

Anticoagulant use, n (%)

0 (0)

tPA, n (%)

5 (63)

Time from symptom onset to tPA (median)

90 min (90–126)

Time from symptom onset to EVT (median)

340 min (256–411)

Platelet count, thousands/μL (mean)

187±68

INR, mean

1.1±0.2

Comorbid conditions, n (%)
Hypertension

5 (63)

Prior TIA/stroke

4 (50)

Prior hemorrhagic stroke

1 (13)

Tobacco user

1 (13)

Atrial fibrillation

2 (25)

Diabetes

1 (13)

Coronary artery disease

3 (38%)

Alcohol abuse

0 (0)

Hyperlipidemia

1 (13)

Occlusion location, n (%)

Outcome Measures

ICA

2 (25)

MCA-M1

3 (38)

MCA-M2

1 (13)

Basilar

2 (25)

The primary safety outcomes were any worsening of
ICH on neuroimaging obtained 24 hours after EVT and
mortality. Additional radiographic outcome measures
included number of passes, reperfusion grade, and procedural time; clinical outcome measures included 90day modified Rankin scale score, NIHSS score at hospital discharge, and complications.

EVT indicates endovascular thrombectomy; ICA, internal carotid artery; INR,
international normalized ratio; IQR, interquartile range; MCA, middle cerebral
artery; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischemic
attack; and tPA, tissue plasminogen activator.

RESULTS

age was 71.9 years (range, 37–90) and 63% (n=5)
were women. Six patients had anterior circulation LVO
with median Alberta Stroke Program Early CT Score
of 8 (interquartile range, 7.25–8.75) and 2 had basilar
artery occlusion (Table 1). Median NIHSS score was 25
(interquartile range, 16.5–28.8), and 5 (63%) received

Eight patients who underwent thrombectomy with concomitant ICH constituted the study cohort. The mean
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TABLE 2.

Procedural, Clinical, and Radiographic Outcomes
All patients

N

8

No. of passes, median (IQR)
Intraprocedural antiplatelet use, n (%)
Procedure duration

2.5 (1.8–3.3)
1 (13)
49±31 min

Final TICI, n (%)
0–2a

0 (0)

2b

6 (75)

3

2 (25)

Primary outcome, n (%)
Worsening of ICH

1 (13)

ICH stability

7 (88)

NIHSS score at hospital discharge,
median (IQR)

22.5 (10.8–42)

90-day modified Rankin scale, n (%)
0–2

2 (25)

0–3

3 (38)

6

4 (50)

ICH indicates intracranial hemorrhage; IQR, interquartile range; NIHSS,
National Institutes of Health Stroke Scale; and TICI, thrombolysis in cerebral
infarction.

FIGURE 1. Example images of prethrombectomy intracranial
hemorrhage. A through C demonstrate patients with hemorrhage
within the affected vascular territory. The patient in D had a right M1
occlusion and had received intravenous tissue plasminogen activator.
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tissue plasminogen activator (tPA) at a median of 90
minutes from symptom onset.
In 6 patients, the location of intraparenchymal hemorrhage was within the infarcted parenchyma (Figure
1). Per ECASS (European-Australasian Acute Stroke
Study) classification,5 3 of these patients were classified as meeting criteria for parenchymal hematoma
type 1, and 1 patient each met criteria for hemorrhage
infarction type 1, hemorrhage infarction type 2, and
parenchymal hematoma type 2. In 2 patients (25%), the
ICH present on hospital admission was contralateral to
the LVO.
All patients underwent EVT at a median of 340
minutes (5.7 hours) after symptoms onset with mTICI
2b (>50% of the affected vascular territory) reperfusion. The median number of passes was 2.5 (interquartile range, 1.8–3.3). All patients received heparinized
saline flushes during EVT per institutional protocols.
One patient required deployment of an intracranial stent
during EVT, requiring an intraprocedural loading dose of
intravenous P2Y12 inhibitor.

Primary Outcome
All patients underwent 24-hour post-EVT neuroimaging; in 7 patients (88%), the initial ICH remained stable.
One patient (13%) met the primary radiographic out-

come of worse ICH on 24-hour postprocedure neuroimaging. In this patient, who underwent intracranial
stent placement and received antiplatelet medications
during EVT, there was a slight increase in infarct-bed
hemorrhagic conversion at 24 hours. There was no
increased mass effect, no worsening neurologic deficit,
and the blood remained stable on repeated imaging
despite ongoing antiplatelet use.

Secondary Outcomes and Complications
Median NIHSS score at hospital discharge was 22.5
(interquartile range, 10.8–42). Two patients (25%)
achieved a modified Rankin scale score of 0 to 2 at
follow-up, and 4 patients (50%) died (Table 2). One
patient died of an ICH, remote from their initial hemorrhage, occurring after EVT. This 90-year-old patient
with thrombocytopenia (78 000 platelets/μL) presented
with a right M1 occlusion and NIHSS score of 17; he
had a small right frontal intraparenchymal hemorrhage
within the infarcted parenchyma. He did not receive
intravenous tPA. Post-EVT neuroimaging revealed massive bilateral parieto-occipital intraparenchymal hemorrhages of unclear etiology, and the patient died.

DISCUSSION
In this analysis of patients undergoing EVT for LVO with
pre-EVT ICH, 7 of 8 (88%) patients demonstrated stability of their hemorrhage after EVT. In the remaining
patient, who required intracranial stenting, there was
minimal worsening of petechial staining on 24-hour

Stroke Vasc Interv Neurol. 2022;2:e000195. DOI: 10.1161/SVIN.121.000195

3

Tonetti et al

Downloaded from http://ahajournals.org by on May 11, 2022

post-EVT neuroimaging, which did not result in significant mass effect or worse neurologic deficit. Overall,
we believe that the cases reported here suggest that
thrombectomy is technically safe and unlikely to independently worsen ICH in this population.
ICH after intravenous tPA occurs in 2% to 7% of
patients, and risk factors have been well described.6
Five patients in this series received intravenous tPA and
most likely had tPA-related hemorrhage; of these, 3
had infarct-bed hemorrhages and 2 had hemorrhages
contralateral to their site of vessel occlusion. None of
these patients in this series who received intravenous
tPA and then underwent EVT had worsening of their
hemorrhage after thrombectomy; these cases suggest
that tPA-related ICH should not alone provide rationale
to withhold thrombectomy.
The median time to EVT reperfusion in this cohort
was 5.7 hours (340 minutes). Although time from symptom onset to intravenous tPA administration is not associated with ICH risk,7,8 the process of blood-brain barrier breakdown after ischemic injury is time dependent.
Patients who undergo delayed thrombectomy may be
more likely to be reimaged than their early-window
counterparts, which may increase the sensitivity that a
pre-EVT hemorrhage is detected and explain why some
patients in this series had lengthy times between symptom onset and thrombectomy.
To the best of the authors’ knowledge, only a single
prior patient with ICH undergoing thrombectomy has
been reported. Zivelonghi et al9 report a quinquagenarian with small-volume subarachnoid hemorrhage who
underwent EVT without subsequent hemorrhagic progression. Incorporating this patient, 8 of 9 patients with
pre-EVT ICH did not experience worsening of ICH after
EVT, and none of the patients reported had worsening
neurologic deficit related to ICH. Reperfusion grade has
been shown to be associated with symptomatic ICH
after thrombectomy,10 possibly by limiting core expansion, and may in turn reduce ICH expansion or contribute to ICH stability in these patients. Taken altogether, EVT may be safe in this population.

Limitations
The major limitations of this report are the small sample
size and retrospective nature.

CONCLUSIONS
In a multi-institution evaluation of 8 patients with ICH at
the time of thrombectomy, 1 patient had radiographic
worsening of hemorrhage, and no patient experienced
clinical worsening related to hemorrhage progression

Pre-EVT ICH

following thrombectomy. These findings suggest that
thrombectomy may be safe in this population.
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